Document:

<PAGE>   1

                                                                   EXHIBIT 10.11

                           COMPOUND PURCHASE AGREEMENT

        THIS COMPOUND PURCHASE AGREEMENT (the "Agreement") is made and entered
into effective as of April 28, 2000 (the "Effective Date"), by and between AXYS
ADVANCED TECHNOLOGIES, INC., a Delaware corporation ("AAT"), and AXYS
PHARMACEUTICALS, INC., a Delaware corporation ("Axys"). AAT and Axys may be
referred to herein individually as a "Party" or, collectively, as the "Parties."

                                    RECITALS

        A. AAT owns certain assets, technology, and intellectual property
relating to combinatorial chemistry and the synthesis of diverse chemistry
libraries using combinatorial techniques.

        B. Axys desires to purchase from AAT quantities of certain compounds
synthesized by AAT using its combinatorial chemistry technology pursuant to its
obligations under existing contracts for use solely in Axys' drug discovery,
development and commercialization programs (but subject to the Limitation).

        C. AAT is willing, pursuant to the following terms and conditions, to
synthesize and sell to Axys such compounds and the related protocols.

        NOW, THEREFORE, the Parties agree as follows:

1.      DEFINITIONS

The following capitalized terms shall have the meanings ascribed to such terms
in the following definitions when used in this Agreement.

        1.1 "AAT CONTRACTS" means the agreements set forth in Schedule 1.1
attached hereto.

        1.2 "AAT KNOW-HOW" means Information that is Controlled by AAT during
this Agreement and relates (a) to the Protocols or the Structural Databases, or
(b) otherwise to the structure or use of the Compounds or to making Compounds or
Derivatives, and is disclosed by AAT hereunder.

        1.3 "AAT PATENTS" means, with respect to a particular Compound or AAT
Know-How, all patents and patent applications Controlled by AAT that claim any
invention relating to such Compound or the manufacture or use thereof or to such
AAT Know-How, but provided that such inventions were made prior to the date such
Compound or AAT Know-How (as applicable) was disclosed to Axys.

        1.4 "AAT TECHNOLOGY" means the AAT Know-How and/or AAT Patents, or any
part or aspect thereof.

<PAGE>   2

        1.5 "AFFILIATE" means, with respect to a particular Party, another
corporation, partnership or similar entity that controls, is controlled by or is
under common control with such Party, but in any case, only for the duration of
the period that such other corporation, partnership or similar entity controls,
is controlled by or is under common control with such Party. For the purposes of
the definition in this Section 1.3, the word "control" (including, with
correlative meaning, the terms "controlled by" or "under the common control
with") means the ownership of at least fifty percent (50%) of the voting stock
(or voting or membership interest, if not a corporation) of such entity. For the
purposes of clarification, it is the parties intent that if a corporation,
partnership or similar entity ceases to control, be controlled by or be under
common control with a particular Party, such entity shall, at the time such
control relationship ceases, cease to have any rights under this Agreement,
including, without limitation, any license rights granted pursuant to this
Agreement. Notwithstanding the foregoing, Axys and AAT shall be deemed not to be
Affiliates of each other.

        1.6 "ASSIGNMENT AGREEMENT" means the Technology Assignment and License
Agreement of even date herewith between Axys and AAT.

        1.7 "COLLABORATION EXCEPTION" has the same meaning as defined in the
Assignment Agreement.

        1.8 "COMBINATORIAL CHEMISTRY LIBRARY" means the aggregate of all the
physical samples of the Compounds in the Libraries provided to Axys hereunder.

        1.9 "COMPOUND" means any individual chemical compound, a physical sample
of which AAT provides to Axys under the terms of Article 2 of this Agreement.

        1.10 "COMPOUND INFORMATION" means, for the purposes of this Agreement,
any confidential or proprietary Information of AAT (or of another person which
has been entrusted to AAT) disclosed by AAT to Axys (pursuant to this
Agreement), including, without limitation, (a) the Protocols, (b) the AAT
Know-How, (c) the Structural Database and (d) any other Information of AAT (or
of another person which has been entrusted to AAT) relating to the Combinatorial
Chemistry Library that may be provided by AAT to Axys hereunder; provided, that
for the purposes of this Agreement, any Information which first becomes known to
or entrusted to AAT after the Effective Date shall not constitute Compound
Information unless it specifically pertains to the structure, manufacture or
activity of specific compounds within the Combinatorial Chemistry Library.

        1.11 "CONTROLLED" means, with respect to any material, Information or
intellectual property right, that AAT owns or has a license to such Information
or intellectual property right with the right to license such Information or
intellectual property right as provided herein without violating any agreement
with a third party.

        1.12 "DELIVERABLES" means the Combinatorial Chemistry Library, the
Libraries therein, the Compounds therein, the Protocols and Structural Databases
relating to such Libraries, and any other Compound Information (including
Compound Information which AAT may deliver to Axys specifically pertaining to
the structure or structure activity of such specific Compounds).

                                       2
<PAGE>   3

        1.13 "DERIVATIVE" means a compound (other than a Compound) made by Axys
based upon the use of (a) Compound Information or (b) any Compound, or (c)
structure-activity Information relating to Compounds.

        1.14 "INFORMATION" means information and data of any type and in any
tangible or intangible form, including without limitation inventions, practices,
methods, techniques, specifications, formulations, formulae, knowledge,
know-how, skill, experience, test data, analytical and quality control data,
stability data, results of studies and patent and other legal information or
descriptions.

        1.15 "LIBRARY" means a collection of different compounds synthesized by
AAT (or its predecessor Axys) pursuant to the obligations under one or more of
the AAT Contracts, which compounds are related to each other by a common
Scaffold and the specific synthetic techniques that AAT used to make such group
of compounds.

        1.16 "LIMITATION" has the same meaning as in the Assignment Agreement.

        1.17 "MAKEUP PAYMENTS" means any and all payments made under Section
3.2(a), (b) and (c).

        1.18 "PROTOCOL" means a detailed set of combinatorial chemistry
synthetic methods and standard operating procedures designed to be used for
synthesizing a Library, in the form customarily prepared by AAT for its
business.

        1.19 "SCAFFOLD" means the chemical substructure common to a set of
Compounds that are synthesized using a particular Protocol.

        1.20 "STRUCTURAL DATABASE" means a complete structural database for all
the Compounds in a particular Library, as delivered on CD/ROM as SD files, or
otherwise, in the form customarily prepared by AAT for its business.

2.      SALE AND TRANSFER OF COMPOUND LIBRARIES

        2.1 NOTICE AND ELECTION TO PURCHASE COMPOUND LIBRARIES. With respect to
any Library that AAT first delivers to an AAT customer (or licensee) after the
Effective Date pursuant to its obligations under one or more AAT Contracts, AAT
shall give Axys written notice of the availability hereunder of such Library for
purchase by Axys (a "Notice of Availability") within thirty (30) days of AAT
first delivering to its customer such Library. Any such Notice of Availability
shall include the full description of the chemical structure of each compound in
such Library. Axys may elect, at any time before the later of April 30, 2003 or
six (6) months after the applicable Notice of Availability is received, to
purchase a six (6) micromole quantity of each (but not fewer than each) of the
compounds in such Library, together with the Protocols for such Library and the
Structural Database for such Library, pursuant to the purchase and delivery
terms of this Agreement, by providing AAT written notice of such election (a
"Purchase Election"). Each Purchase Election is irrevocable. In addition to the
foregoing rights, with any Notice of Availability delivered by AAT as provided
above, AAT may, at its discretion, offer to Axys that Axys purchase, in lieu of
the Library covered by such Notice of Availability, a different library of
compounds produced by AAT outside the scope of

                                       3
<PAGE>   4

this Agreement. Any such offer shall also be deemed a "Notice of Availability"
regarding the compounds in such library for which AAT shall have the right to
elect to purchase such compounds by making a Purchase Election as provided
above. As to any such library of compounds for which Axys makes such Purchase
Election, such library shall be deemed to be a "Library" and such compounds
shall be deemed to be "Compounds" for all purposes hereunder.

        2.2 DELIVERY OF DELIVERABLES. Upon receiving from Axys a Purchase
Election with respect to a particular Library, AAT shall commence the delivery
to Axys of all the Compounds in such Library, and the Structural Database for
such Library and all Protocols relating to such Compounds (which are provided
for use subject to the licenses granted by AAT herein). The Compounds shall be
delivered in 96 well plates with an 88 well array format with approximately six
(6) micromoles of each Compound present in the shipment, or any other format
agreed to by the Parties. AAT shall complete the delivery of such Library and
other Deliverables to Axys within thirty (30) days of receipt of such Purchase
Election. Risk of loss for and title to the Compounds provided by AAT to Axys
under this Agreement shall pass from AAT to Axys upon delivery to a common
carrier F.O.B. AAT's factory. Each respective Library delivered to Axys
hereunder shall comply with the specifications set forth in the governing
specifications schedule of the applicable AAT Contract. AAT shall deliver a
certificate of analysis with each Library specifying the results of analysis to
show conformance with the specifications set forth in such governing
specifications schedule.

        2.3 USE OF DELIVERABLES BY AXYS. Axys covenants that it will not use,
and will not allow anyone else to use, the Deliverables, except as expressly
permitted by this Section 2.3. Axys and its Affiliates shall have the right to
use, within the scope of the Limitation and not otherwise, the Deliverables.
Axys and its Affiliates shall be permitted to disclose and sublicense use of the
Deliverables only (a) to one or more Collaboration partners of Axys or its
Affiliate solely for the performance of work within the Collaboration Exception
and not otherwise, and (b) to third party contractors for the performance of
work, within the scope of the Limitation and not otherwise on Axys' or its
Affiliate's behalf, in either case as part of Axys' or its Affiliate's internal
research and/or development work in the area of drug discovery, development and
commercialization (or within the scope of the Collaboration Exception) and
subject to appropriate written non-disclosure and limitation-of-use agreements.
Further, Axys or its Affiliate or permitted sublicensee may license, use, offer
for sale, sell, manufacture, have manufactured and otherwise market and
commercialize (a) any pharmaceutical or diagnostic products containing a
particular active Compound or Derivative, or (b) any such Compound or Derivative
in bulk material for use in manufacturing such pharmaceutical products. Axys,
its Affiliates and permitted third party sublicensees (as provided above in this
Section) may use the Information generated by the permitted uses of the
Deliverables for any purpose, subject only to the Non-Competition and
Non-Disclosure Agreement. Axys shall use reasonable efforts to cause the
compliance of each of its Affiliates and of its and their directors, officers,
employees, agents, consultants, contractors and collaborators with all such
restrictions regarding the Deliverables transferred or disclosed to such person.

        2.4 AXYS' RIGHT TO DERIVATIVES. Axys and its Affiliates shall have a
worldwide, royalty-free, irrevocable (except for uncured material breach by
Axys), non-exclusive right under the AAT Technology to synthesize and use
Derivatives within the scope of the Limitation and not otherwise, sublicenseable
and transferable to the same extent as described in Section 2.3 and

                                       4
<PAGE>   5

not otherwise. Axys agrees, for itself and its Affiliates, not to synthesize or
use Derivatives except within the scope of the Limitation and not to sublicense
or transfer Derivatives except to the same extent described in Section 2.3.

        2.5 USE OF DELIVERABLES BY AAT. This Agreement shall not in any way
limit AAT's rights to use, disclose, license, transfer or sell to anyone the
Deliverables.

        2.6 RESUPPLY OF LIBRARY. Upon written request to AAT by Axys, AAT will
resupply any particular Library or Libraries (to the extent available in AAT
then-existing inventory) by supplying Axys all (but not less than all) the same
Compounds in the requested Library or Libraries, in the same format and same
quantities (or such lesser amounts as are available from AAT) as provided under
Section 2.2, and subject to the payments as set forth in Section 5.2.

        2.7 RESYNTHESIS AND SUPPLY OF COMPOUNDS. Upon written request to AAT by
Axys, AAT will negotiate in good faith with Axys the terms and conditions under
which AAT would resynthesize and supply to Axys any particular Compound(s).

        2.8 EXCEPTION. Notwithstanding any contrary term or provision of this
Agreement, it is understood and agreed that Axys shall have the right to use the
Deliverables and any Derivatives for the specific purposes of and for performing
its obligations under, and subject to the terms of, that certain agreement
between Axys and Cytovia, Inc., dated March 15, 2000.

3.      TAKE OR PAY OBLIGATIONS

        3.1 ANNUAL MINIMUMS.

            (a) Axys agrees to provide, on or before April 30, 2001, Purchase
Elections carrying an aggregate purchase price of no less than the First Year
Requirement (as defined below).

            (b) Axys separately agrees to provide, after April 30, 2001 and on
or before April 30, 2002, Purchase Elections carrying an aggregate purchase
price of no less than the Second Year Requirement (as defined below).

            (c) Axys separately agrees to provide, after April 30, 2002 and on
or before April 30, 2003, Purchase Elections carrying an aggregate purchase
price of no less than the difference of (i) the Total Price, minus (ii) the sum
of (A) the aggregate purchase price under all Purchase Elections delivered
before April 30, 2003, plus (B) the sum of any and all Makeup Payments.

            (d) The "First Year Requirement" is the lesser of (i) the product of
(A) the total number of Compounds in all Libraries for which a Notice of
Availability was delivered on or before April 1, 2001, times (B) $12.00, or (ii)
$250,000. The "Second Year Requirement" is the lesser of (i) the product of (A)
the total number of Compounds in all Libraries for which a Notice of
Availability was delivered after April 1, 2001 and on or before April 1, 2002,
times (B) $12.00, or (ii) $500,000. The "Total Price" is the lesser of (A)
product of (i) the total number of Compounds in all libraries for which a Notice
of Availability was delivered on or before April 1, 2003, times (ii) $12.00, and
(B) $3,350,000.

                                       5
<PAGE>   6

        3.2 MAKEUP PAYMENTS.

            (a) If Axys fails to meet the minimums of Section 3.1(a), it shall
pay AAT before June 30, 2001 the excess of the First Year Requirement over the
aggregate purchase price in the Purchase Elections delivered on or before April
30, 2001.

            (b) If Axys fails to meet the minimums of Section 3.1(b), it shall
pay AAT before June 30, 2002 the excess of the Second Year Requirement over the
aggregate purchase price in the Purchase Elections delivered after April 30,
2001 and on or before April 30, 2002.

            (c) If Axys fails to meet the minimums of Section 3.1(c), it shall
pay AAT before June 30, 2003 the excess of the Total Price over the sum of (i)
the aggregate purchase price under all Purchase Elections delivered on or before
April 30, 2003, plus (ii) the sum of any and all payments made under Section
3.2(a) and (b).

            (d) Axys shall not be entitled to delivery of any Compounds or
Protocols or to any other consideration, in respect of the Makeup Payments,
except for the application in the formula in Section 3.2(c). Any payments made
to AAT pursuant to this Section 3.2 shall be the sole and exclusive remedy of
AAT for any failure of Axys to meet the requirements in Section 3.1.

4.      LICENSE AND LIMITATIONS

        4.1 LIMITED COMMERCIAL LICENSE. Subject to the terms of this Agreement
(including Section 2.3), AAT hereby grants Axys a limited, non-exclusive,
worldwide, perpetual (subject to termination under Article 9) license under the
AAT Technology for Axys and its Affiliates and permitted sublicensees to use,
practice and commercially exploit the AAT Technology within the scope of the
Limitation, and to use, import, offer for sale, sell and manufacture (a) any
pharmaceutical or diagnostic products containing a particular active Compound or
Derivative, or (b) any such Compound or Derivative in bulk material for use in
manufacturing such pharmaceutical or diagnostic products.

        4.2 LIMITATIONS. This Agreement shall not in any way limit AAT's rights
to use all its Deliverables, technology, Information and intellectual property
rights for its own purposes and to sell, license or disclose such Deliverables,
technology, Information and intellectual property rights to third parties
without restriction. This Agreement shall not in any way limit Axys' rights to
use for its own purposes and to sell, license or disclose to third parties
without restriction any compound that is discovered or synthesized by Axys or
its Affiliates completely independent of any activity permitted under this
Agreement and without use of or reliance on any Compound Information or other
Deliverables; however, certain such limits may be imposed under a
Non-Competition and Non-Disclosure Agreement between Axys and Discovery Partners
International, Inc.

5.      PAYMENT

        5.1 PAYMENT FOR COMPOUNDS. Axys shall pay AAT a purchase price for the
Compounds in a Library, and the Structural Database and Protocols for such
Library, delivered hereunder equal to twelve dollars ($12) per Compound that AAT
delivers to Axys in compliance

                                       6
<PAGE>   7

with the obligations of Section 2.2 of this Agreement. Axys shall make such
payment within thirty (30) days of receipt of an applicable invoice after
completion of shipment of the applicable Library and related Structural Database
and Protocols by AAT, subject to Axys' right to inspect each shipment and reject
non-conforming Deliverables within such thirty (30) day period. Any Deliverables
not rejected within such thirty (30) day period shall be deemed to have been
accepted.

        5.2 PAYMENT FOR COMPOUND RESUPPLY. Axys shall pay AAT a purchase price
for the resupply to Axys, under Section 2.6, of requested Compounds equal to one
dollar fifty cents ($1.50) per micromole of such Compounds that AAT delivers to
Axys under Section 2.6. Axys shall make such payment within thirty (30) days of
completion of shipment of the applicable Compounds, subject to Axys' right to
inspect each shipment and reject non-conforming Deliverables within such thirty
(30) day period. Any Deliverables not rejected within such thirty (30) day
period shall be deemed to have been accepted..

        5.3 BANK ACCOUNT. All payments payable by Axys to AAT under this
Agreement shall be made by wire transfer remittance to the bank account
designated by AAT.

        5.4 RELATED COSTS. Axys shall be responsible for payment of all shipping
or other transportation charges and insurance costs and any sales, transfer,
excise, export or other tax and of any customs tax or duties assessed on the
sale or transfer of such Compounds under the terms of this Agreement, but
excluding taxes based upon net income of AAT.

6.      INTELLECTUAL PROPERTY MATTERS

        6.1 OWNERSHIP. The sale to Axys of the Compounds hereunder does not
involve the sale or transfer of AAT intellectual property rights (if any)
relating thereto and relating to the other Deliverables, which AAT retains,
subject to a nonexclusive license right as expressly contemplated under Section
2.3 and Section 4.1. AAT shall own the entire right, title and interest in and
to any inventions and Information, and all intellectual property rights therein,
developed solely by employees or agents of AAT or its Affiliates in the course
of this Agreement. Axys shall own the entire right, title and interest in and to
any inventions and Information, and all intellectual property rights therein,
developed solely by employees or agents of Axys or its Affiliates in the course
of this Agreement.

        6.2 LIMITATION ON PATENT APPLICATIONS. If Axys or its Affiliate or
permitted sublicensee has both data indicative of efficacy of a particular
Compound or Derivative and a reasonable belief that it will develop and
commercialize such particular Compound or Derivative, Axys or its Affiliate or
permitted sublicensee may file and prosecute a patent application that
specifically claims the composition of matter and/or method of use of such
particular Compound. Except as provided in the preceding sentence, Axys agrees
(for Axys and its Affiliates) to use its good faith efforts to avoid filing or
prosecuting any patent applications that (a) specifically or generically claim
the composition of matter of any particular Compound and/or the method of use of
any Compound; provided that the foregoing shall not apply with respect to any
Compound having the same chemical structure as a chemical compound that is
discovered by Axys or its Affiliates completely independent of any activity
permitted under this Agreement and without use of or reliance on any Compound
Information or other Deliverables

                                       7
<PAGE>   8

or (b) describes in the specifications, but does not claim, a particular
Compound; provided, that if such description is reasonably necessary to support
the claimed invention, then such description may be included in the
specification.

        6.3 LIMITED CROSS-LICENSE. Axys hereby grants to AAT a non-exclusive,
world-wide, perpetual (subject to termination by Axys under Section 9.2),
royalty-free license, with right to sublicense, under current and future issued
patents owned by Axys or its Affiliates and filed pursuant to Section 6.2, that
specifically or generically claim a Compound, but excluding from the foregoing
license: (i) any Axys patent claiming an invention comprising a Compound that is
discovered by Axys or its Affiliates completely independent of any activity
permitted under this Agreement and without use of or reliance on any AAT
Technology or other Compound Information or other Deliverables, and (ii) (for
the duration of such program as an actively pursued program) any license right
to use or sell, for any purpose other than screening or creating derivatives,
any Compound that Axys or its Affiliate or permitted sublicensee is actively
pursuing as a drug or other product with activity (such as a pesticide), such
active pursuit being demonstrated by an active and ongoing program of research
and development or marketing for which funds and personnel have been allocated.

        6.4 ENFORCEMENT OF PATENTS. If Axys becomes aware of any actions of a
third party that it considers infringing upon any AAT Patent, it shall use
reasonable efforts to notify AAT and provide all evidence of such infringement
that is reasonably available. AAT shall have the sole and exclusive right, at
its own expense, to attempt to terminate such infringement by commercially
appropriate steps, including suit, but shall have no obligation to Axys to do
so. Any amounts recovered by AAT, whether by settlement or judgment, shall be
retained by AAT.

        6.5 THIRD PARTY PATENT ALLEGATIONS. If any warning letter or other
notice of infringement is received by a Party, or action, suit or proceeding is
brought against a Party alleging infringement of a patent right of any third
party in the manufacture, use or sale of a Deliverable or Derivative or use or
practice of the Compound Information or any AAT Patents, the Parties shall
promptly discuss and decide the best way to respond.

7.      CONFIDENTIALITY

        7.1 CONFIDENTIALITY OBLIGATIONS. Axys agrees that the Compound
Information shall be subject to the provisions of Article 6 of the Assignment
Agreement.

        7.2 PUBLICATIONS. Subject to the terms of Section 7.1, Axys may publish
Information discovered or developed in its research, development or
commercialization activities derived from use of any Compounds or Deliverables
without the consent of or notice to AAT.

8.      INDEMNIFICATION

        8.1 INDEMNIFICATION BY AXYS. Axys shall indemnify, defend and hold AAT
and its agents, employees, officers and directors (the "AAT Indemnitees")
harmless from and against any and all liability, damage, loss, cost or expense
(including reasonable attorneys' fees) arising out of third party claims or
suits related to (a) Axys' or its Affiliate's negligence, willful misconduct or
breach of this Agreement; or (b) the manufacture, use or sale of Compounds by
Axys or anyone acting under color of authority from Axys, or the manufacture,
use or sale, by

                                       8
<PAGE>   9

Axys or anyone acting under color of authority from Axys, of Derivatives, except
to the extent such claims or suits result from negligence or willful misconduct
of or breach of this Agreement by any of the AAT Indemnitees. Upon the assertion
of any such claim or suit, the AAT Indemnitees shall promptly notify Axys
thereof, and Axys shall appoint counsel reasonably acceptable to the AAT
Indemnitees to represent the AAT Indemnitees with respect to any claim or suit
for which indemnification is sought, provided that Axys shall have sole control
over the defense and settlement of such claim or suit.

        8.2 INDEMNIFICATION BY AAT. AAT shall indemnify, defend and hold Axys
and its agents, employees, officers and directors (the "Axys Indemnitees")
harmless from and against any and all liability, damage, loss, cost or expense
(including reasonable attorney's fees) arising out of third party claims or
suits related to (a) AAT's or its Affiliates' negligence, willful misconduct or
breach of this Agreement, (b) the manufacture, use or sale to third parties by
AAT or anyone acting under color of authority granted after the Effective Date
by AAT, (provided such party is not Axys) of Compounds or products containing
such Compounds or any compound based upon or derived therefrom, or (c) personal
or property damage arising directly from the manufacturing of the Compounds by
AAT, except to the extent that such claims or suits result from negligence or
willful misconduct of or breach of this Agreement by any of the Axys
Indemnitees. Upon the assertion of any such claim or suit, the Axys Indemnitees
shall promptly notify AAT thereof, and AAT shall appoint counsel reasonably
acceptable to the Axys Indemnitees to represent the Axys Indemnitees with
respect to any claim or suit for which indemnification is sought, provided that
AAT shall have sole control over the defense and settlement of such claim or
suit. Axys may nevertheless retain co-counsel at its own expense.

        8.3 SETTLEMENT. No settlement of any claim or suit covered by this
Article 8 may be effected by the indemnifying party without the consent of an
indemnified party unless the indemnified party is not required to provide any
consideration with respect thereto.

9.      TERMINATION AND EXPIRATION

        9.1 TERM. This Agreement shall commence upon the Effective Date and,
unless earlier terminated as provided herein, shall expire on December 31, 2003.

        9.2 TERMINATION UPON MATERIAL BREACH.

            (a) Failure by a Party to comply with any of its material
obligations contained herein shall entitle the Party not in default to give to
the Party in default notice specifying the nature of the default, requiring it
to make good or otherwise cure such default, and stating its intention to
terminate if such default is not cured. If such default is not cured within
ninety (90) days after the date of such notice (or, if such default cannot be
cured within such ninety (90) day period, if the Party in default does not
commence and diligently continue actions to cure such default), the Party not in
default shall be entitled, without prejudice to any of its other rights
conferred on it by this Agreement, and in addition to any other remedies
available to it by law or in equity, to terminate this Agreement.

            (b) The right of a Party to terminate this Agreement, as provided
above, shall not be affected in any way by its waiver or failure to take action
with respect to any prior default.

                                       9
<PAGE>   10

A Party may waive its right to terminate this Agreement with respect to a
particular default, provided that any such waiver shall not constitute a waiver
of, and such Party shall retain all rights to pursue, any and all other remedies
it may have at law or in equity of such default by the other Party.

        9.3 CONSEQUENCES OF TERMINATION.

            (a) Upon termination of this Agreement by Axys pursuant to Section
9.2 for the uncured material breach of AAT, then without prejudice to any other
remedy of Axys, (i) Section 9.4 shall apply; and (ii) all obligations and rights
of AAT to provide additional Compounds and to receive future Makeup Payments
shall terminate.

            (b) Upon termination of this Agreement by AAT pursuant to Section
9.2 for the uncured material breach of Axys, then without prejudice to any other
remedy of AAT (i) all rights granted to Axys under this Agreement, except for
those referred to in the sections set forth in Section 9.4, shall terminate;
(ii) with respect to any physical sample of a Compound delivered by AAT but not
paid for by Axys within thirty (30) days of delivery, Axys shall return all
existing physical samples of such Compounds and Axys may not further use such
Compounds and the related Deliverables; (iii) all obligations of AAT to provide
additional Compounds and the related Deliverables shall terminate; and (iv) Axys
shall promptly return to AAT or destroy all originals, manifestations, analyses,
descriptions, reflections and copies of Compound Information, but excluding from
the foregoing any such Compound Information specifically relating to Compounds
(and their related Protocols and Structural Information) for which Axys has
completed payment as required herein.

        9.4 ACCRUED RIGHTS; SURVIVING OBLIGATIONS.

            (a) Termination or expiration of this Agreement for any reason shall
be without prejudice to any rights which shall have accrued to the benefit of a
Party prior to such termination or expiration. Such termination or expiration
shall not relieve a Party from obligations which are expressly indicated to
survive termination or expiration of this Agreement.

            (b) Without limiting the foregoing, Articles 1, 6, 7, 8 and 9 of
this Agreement shall survive the expiration or termination of this Agreement
indefinitely.

            (c) In addition to those sections set forth in subsection (b),
Sections 2.3, 2.4, and 4.1 shall survive indefinitely the termination or
expiration of this Agreement, subject to compliance by Axys, its Affiliates and
any permitted sublicensees with all limitations set forth in such Sections and
the rest of this Agreement.

10.     MISCELLANEOUS PROVISIONS

        10.1 RELATIONSHIP OF THE PARTIES. Nothing in this Agreement is intended
or shall be deemed to constitute a joint venture, partnership, agency or
employer-employee relationship between the Parties. Neither Party shall incur or
purport to incur any debts or make or purport to make any commitments for the
other.

                                       10
<PAGE>   11

        10.2 ASSIGNMENTS. Except as expressly provided herein, neither this
Agreement nor any interest hereunder shall be assignable, nor any other
obligation delegable, by a Party without the prior written consent of the other;
provided, however, that a Party may assign this Agreement to any successor in
interest by way of merger, acquisition or sale of all or substantially all of
its assets in a manner such that the assignee shall be liable and responsible
for the performance and observance of all such Party's duties and obligations
hereunder. This Agreement shall be binding upon the successors and permitted
assigns of the Parties. Any assignment not in accordance with this Section 10.2
shall be void.

        10.3 DISCLAIMER OF WARRANTIES. EXCEPT FOR THE WARRANTIES SET FORTH IN
SECTION 10.4, THE PARTIES DO NOT BY VIRTUE OF THIS AGREEMENT GRANT, AND HEREBY
EXPRESSLY DISCLAIM THAT BY VIRTUE OF THIS AGREEMENT THEY GRANT, ALL WARRANTIES,
EXPRESS, STATUTORY OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF THIRD
PARTY RIGHTS.

        10.4 REPRESENTATIONS AND WARRANTIES. Each Party represents and warrants
to the other Party that, as of the date of this Agreement:

                (i) such Party is duly organized and validly existing under the
laws of the state of its incorporation and has full corporate power and
authority to enter into this Agreement and to carry out the provisions hereof;

                (ii) such Party has taken all corporate action necessary to
authorize the execution and delivery of this Agreement and the performance of
its obligations under this Agreement; and

                (iii) this Agreement is a legal and valid obligation of such
Party, binding upon such Party and enforceable against such Party in accordance
with the terms of this Agreement, except as such enforcement may be limited by
applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or
other similar laws affecting creditors' rights, and subject to general equity
principles and to limitations on availability of equitable relief, including
specific performance. All consents, approvals and authorizations from all
governmental authorities or other third parties required to be obtained by such
Party in connection with this Agreement have been obtained.

In addition, Axys represents and warrants to AAT that, as of the date of this
Agreement and as of each other day during the term of this Agreement, Axys has
obtained and shall have obtained written confidentiality agreements from each of
its employees who have access to the Compound Information, whether in the form
of general confidentiality agreements from the employees obtained at the time of
commencement of such employees' employment by Axys or otherwise, which
agreements obligate such persons to maintain as confidential all confidential
information obtained by Axys in confidence from a third party.

        10.5 FURTHER ACTIONS. Each Party agrees to execute, acknowledge and
deliver such further instruments and to do all such other acts as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

                                       11
<PAGE>   12

        10.6 FORCE MAJEURE. The failure of a Party to perform any obligation
under this Agreement by reason of acts of God, acts of governments, riots, wars,
strikes, accidents or deficiencies in materials or transportation or other
similar causes beyond its control for the duration thereof and for thirty (30)
days thereafter shall not be deemed to be a breach of this Agreement.

        10.7 NO TRADEMARK RIGHTS. No right, express or implied, is granted by
this Agreement to a Party to use in any manner the name or any other trade name
or trademark or servicemark of the other Party.

        10.8 ENTIRE AGREEMENT OF THE PARTIES; AMENDMENTS. This Agreement
constitutes and contains the entire understanding and agreement of the Parties
respecting the subject matter hereof and cancels and supersedes any and all
prior negotiations, correspondence, understandings and agreements between the
Parties, whether oral or written, regarding such subject matter. No waiver,
modification or amendment of any provision of this Agreement shall be valid or
effective unless made in writing after the Effective Date and signed by a duly
authorized officer of each Party. Further, nothing in this Agreement is intended
to, or shall be construed to, limit the rights granted by AAT to Axys or by Axys
to AAT in the Assignment Agreement; nor limit the effect of any non-competition
and non-disclosure agreement which Axys and any acquirer of AAT enter into.

        10.9 CAPTIONS. The captions and headings to this Agreement are for
convenience only, and are to be of no force or effect in construing or
interpreting any of the provisions of this Agreement.

        10.10 GOVERNING LAW, CONSENT TO JURISDICTION AND FORUM SELECTION. This
Agreement shall be governed by and construed in accordance with the laws of the
State of California applicable to contracts executed and performed in such
State, without giving effect to conflicts of laws principles. The parties hereto
agree that all actions or proceedings arising in connection with this Agreement
(as to proceedings initiated by Axys) shall be initiated and tried exclusively
in the State and Federal courts located in the County of San Diego, State of
California. The parties hereto agree that all actions or proceedings arising in
connection with this Agreement (as to proceedings initiated by AAT) shall be
initiated and tried exclusively in the State and Federal courts located in the
County of San Francisco, State of California. The aforementioned choice of venue
is intended by the parties to be mandatory and not permissive in nature, thereby
precluding the possibility of litigation between the parties with respect to or
arising out of this Agreement in any jurisdiction other than that specified in
this Section 10.10. Each party hereby waives any right it may have to assert the
doctrine of forum non conveniens or similar doctrine or to object to venue with
respect to any proceeding brought in accordance with this paragraph, and
stipulates that the State and Federal courts located in the County of San Diego,
State of California (as to proceedings initiated by Axys) or in the County of
San Francisco, State of California (as to proceedings initiated by AAT) shall
have in personam jurisdiction and venue over each of them for the purposes of
litigating any dispute, controversy or proceeding arising out of or related to
this Agreement. Each party hereby authorizes and accepts service of process
sufficient for personal jurisdiction in any action against it as contemplated by
this Section 10.10 by registered or certified mail, return receipt requested,
postage prepaid, to its address for the giving of notices as set forth in this
Agreement, or in the

                                       12
<PAGE>   13

manner set forth in Section 10.11 of this Agreement for the giving of notice.
Any final judgment rendered against a party in any action or proceeding shall be
conclusive as to the subject of such final judgment and may be enforced in other
jurisdictions in any manner provided by law

10.11 NOTICES AND DELIVERIES. All notices, requests and other communications
hereunder must be in writing and will be deemed to have been duly given only if
delivered personally or by facsimile transmission with answer back confirmation
or mailed (first class, postage prepaid) or by overnight courier to the parties
at the following addresses or facsimile numbers:

            If to Axys, to:

                   Axys Pharmaceuticals, Inc.
                   180 Kimball Way
                   South San Francisco, CA 94080
                   Facsimile No.: (650) 829-1067
                   Attention:  John Walker, Chairman and Chief Executive Officer

            with copies to:

                   Cooley Godward LLP
                   Five Palo Alto Square
                   3000 El Camino Real
                   Palo Alto, CA  94306-2155
                   Facsimile No.: (650) 857-6663
                   Attention:  Barclay James Kamb, Esq.

            If to AAT, to:

                   Axys Advanced Technologies, Inc.
                   c/o Discovery Partners International, Inc.
                   9640 Towne Centre Drive
                   San Diego, CA  92121
                   Facsimile No.: (858) 455-8088
                   Attention:  Riccardo Pigliucci, Chairman

                                       13
<PAGE>   14

                      with copies to:

                      Brobeck, Phleger & Harrison LLP
                      12390 El Camino Real
                      San Diego, CA  92130
                      Facsimile No.: (858) 720-2555
                      Attention:  Hayden Trubitt, Esq.

        10.12 WAIVER. A waiver by either Party of any of the terms and
conditions of this Agreement in any instance shall not be deemed or construed to
be a waiver of such term or condition for the future, or of any subsequent
breach hereof. All rights, remedies, undertakings, obligations and agreements
contained in this Agreement shall be cumulative and none of them shall be in
limitation of any other remedy, right, undertaking, obligation or agreement of
either Party.

        10.13 COMPLIANCE WITH LAW. Nothing in this Agreement shall be deemed to
permit Axys to export, reexport or otherwise transfer any Deliverable without
compliance with all applicable laws. Axys agrees not to export, reexport or
otherwise transfer any Deliverable without full compliance with all applicable
laws.

        10.14 SEVERABILITY. When possible, each provision of this Agreement will
be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Agreement is held to be prohibited by or invalid
under applicable law, such provision will be ineffective only to the extent of
such prohibition or invalidity, without invalidating the remainder of this
Agreement.

        10.15 COUNTERPARTS. This Agreement may be executed in two counterparts,
each containing the signature of one Party. Each counterpart shall be deemed an
original, and both counterparts together shall constitute one and the same
agreement.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       14
<PAGE>   15

        IN WITNESS WHEREOF, the Parties have caused this Compound Purchase
Agreement to be executed by their respective duly authorized officers as of the
day and year first above written, each copy of which shall for all purposes be
deemed to be an original.

                                            AXYS PHARMACEUTICALS, INC.

                                            By:     /s/ William J. Newell
                                                --------------------------------
                                            Name:   William J. Newell
                                                  ------------------------------
                                            Title:  Senior Vice President
                                                   -----------------------------

                                            AXYS ADVANCED TECHNOLOGIES, INC.

                                            By:     /s/ William J. Newell
                                                --------------------------------
                                            Name:   William J. Newell
                                                  ------------------------------
                                            Title:  Secretary
                                                   -----------------------------

                 [SIGNATURE PAGE TO COMPOUND PURCHASE AGREEMENT]

                                       15
<PAGE>   16

                                  SCHEDULE 1.1

                                  AAT CONTRACTS

Research Agreement with Pharmacia & Upjohn dated February 29, 1996, as amended.

Combinatorial Chemistry Agreement with Warner-Lambert Company dated May 15,
1998.

Combinatorial Chemistry Agreement with Signal Pharmaceuticals, Inc. dated July
6, 1998.

Combinatorial Chemistry Agreement with Rhone-Poulenc Rorer dated December 22,
1998.

Combinatorial Chemistry Agreement with Protein Design Labs, Inc. dated December
28, 1998.

Combinatorial Chemistry Agreement with Novalon Pharmaceutical Corporation dated
June 28, 1999.

Combinatorial Chemistry Agreement with Daiichi Pharmaceutical Co., Ltd. dated
June 30, 1999.

Combinatorial Chemistry Agreement with Allergan, Inc. dated September 27, 1999

Combinatorial Chemistry Agreement with Elitra Pharmaceuticals Inc., dated
September 30, 1999

Combinatorial Chemistry Agreement with Novartis Institute for Functional
Genomics, Inc., dated December 8, 1999

Combinatorial Chemistry Agreement with L'Oreal Group, dated December 20, 1999

Combinatorial Chemistry Agreement with Monsanto, dated December 21, 1999

Combinatorial Chemistry Agreement with Cephalon, Inc., dated December 21, 1999

Combinatorial Chemistry Agreement with Bristol-Myers Squibb Company, dated
December 31, 1999

                                       16<PAGE>   1

                                                                   EXHIBIT 10.14

                                RIGHTS AGREEMENT

        THIS RIGHTS AGREEMENT is made as of the 5th day of May, 2000, by and
among Structural Proteomics, Inc., a New Jersey corporation ("SP"), Richard
Fine, Boris Klebansky and Arnold Hagler (the "FOUNDERS") and Discovery Partners
International, Inc., a California corporation ("DPI").

                                    RECITALS

        WHEREAS, SP, Richard Fine, Boris Klebansky and DPI are parties to the
Stock Purchase Agreement of even date herewith (the "PURCHASE AGREEMENT");

        WHEREAS, the Founders are founders and shareholders of SP;

        WHEREAS, in order to induce DPI to enter into the Purchase Agreement and
to invest funds in SP pursuant to the Purchase Agreement, SP and the Founders
agree to grant to DPI certain rights to acquire equity securities of SP and the
parties hereby agree that this Agreement shall govern certain other rights of
the parties with respect to the matters set forth herein;

        NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

        1. Right of First Offer.

        Subject to the terms and conditions specified in this Section 1, SP
hereby grants to DPI a right of first offer with respect to future sales by SP
of its Shares (as hereinafter defined).

           Each time SP proposes to offer any shares of, or securities
convertible into or exercisable for any shares of, any class of its capital
stock ("SHARES"), SP shall first make an offering of such Shares to DPI in
accordance with the following provisions:

           1.1 SP shall deliver written notice ("OFFERING NOTICE") to DPI
stating (i) its bona fide intention to offer such Shares, (ii) the number of
such Shares to be offered, and (iii) the price and terms, if any, upon which it
proposes to offer such Shares.

           1.2 Within 20 calendar days after receipt of the Offering Notice, DPI
may elect to purchase or obtain, at the price and on the terms specified in the
Offering Notice, up to that portion of such Shares which equals the proportion
that the number of shares of common stock issued and held, or issuable upon
conversion of any securities then held that are convertible or exchangeable into
common stock, by DPI bears to the total number of shares of common stock of SP
then outstanding (assuming full conversion and exercise of all convertible or
exercisable securities) as of the date of the Offering Notice. DPI shall make
such election by giving written notice to SP.

           1.3 SP may, during the 60-day period following the expiration of the
period provided in Section 1.2 hereof, offer the remaining unsubscribed portion
of such Shares referred to in the Offering Notice and not purchased by DPI
(including the portion not offered to DPI) to any person or persons at a price
not less than, and upon terms no more favorable to the offeree

<PAGE>   2

than those specified in the Offering Notice. If SP does not enter into an
agreement for the sale of the Shares within such period, or if such agreement is
not consummated within 60 days of the execution thereof, the right provided
hereunder shall be deemed to be revived and such Shares shall not be offered
unless first reoffered to DPI in accordance herewith.

           1.4 The right of first offer in this Section 1 shall not be
applicable (i) to the issuance of equity securities in connection with a
strategic alliance or capital equipment lease transaction, or (ii) to or after
consummation of a bona fide, firmly underwritten public offering of shares of
common stock, registered under the Securities Act of 1933, as amended (the
"ACT") pursuant to a registration statement on Form S-1, at an offering price of
at least $10,000,000 in the aggregate.

           1.5 The right of first offer in this Section 1 shall terminate in the
event (a) DPI does not elect pursuant to Section 1.2 to purchase Shares offered
to it pursuant to this Section 1 and (b) all of such Shares are then
successfully sold to others within the 60-day period as contemplated by Section
1.3.

        2. Founders Right to Exchange SP Stock for DPI Stock. Subject to the
terms and conditions specified in this Section 2 and the valuation mechanism set
forth in Section 4, DPI hereby grants to the Founders (who must all act
together, or else not at all) certain option rights, exercisable only after
DPI's IPO, to exchange shares of the common stock of SP then held by such
Founders for shares of Common Stock of DPI (collectively, the "FOUNDERS PUT
OPTIONS"). The Founders Put Options shall apply with respect to the shares of
common stock of SP held by such Founders (and not then owned by DPI) upon the
closing of DPI's IPO (the "IPO-TIME SHARES").

           2.1 Founders Put Options.

               (a) First Put Option. By valid delivery of a Put Option Notice
(as set forth below), the Founders may elect to exchange on the first
anniversary of the closing of the IPO (the "FIRST ANNIVERSARY DATE") up to
twenty-five percent (25%) of the IPO-Time Shares (less any IPO-Time Shares
previously sold to DPI under Section 2 or 3) for shares of common stock of DPI.

               (b) Second Put Option. By valid delivery of a Put Option Notice
(as set forth below), the Founders may elect to exchange on the second
anniversary of the closing of the IPO (the "SECOND ANNIVERSARY DATE") up to
fifty percent (50%) of the IPO-Time Shares (less any IPO-Time Shares previously
sold to DPI under Section 2 or 3) for shares of common stock of DPI.

               (c) Third Put Option. By valid delivery of a Put Option Notice
(as set forth below), the Founders may elect to exchange on the third
anniversary of the closing of the IPO (the "THIRD ANNIVERSARY DATE") up to
seventy-five percent (75%) of the IPO-Time Shares (less any IPO-Time Shares
previously sold to DPI under Section 2 or 3) for shares of common stock of DPI.

               (d) Fourth Put Option. By valid delivery of a Put Option Notice
(as set forth below), the Founders may elect to exchange on the fourth
anniversary of the closing of

                                      -2-
<PAGE>   3

the IPO (the "FOURTH ANNIVERSARY DATE") up to one hundred percent (100%) of the
IPO-Time Shares (less any IPO-Time Shares previously sold to DPI under Section 2
or 3) for shares of common stock of DPI. Each of the First Anniversary Date, the
Second Anniversary Date, the Third Anniversary Date and the Fourth Anniversary
Date may also be referred to herein as an "ANNIVERSARY DATE").

           2.2 Put Option Notice. Each time the Founders elect to exercise a
Founders Put Option, the Founders shall deliver not less than thirty (30) days
prior to the applicable Anniversary Date of the IPO a written notice (each a
"PUT OPTION NOTICE") to DPI. Such Put Option Notice shall be signed by each of
the Founders and shall state the numbers of Option Shares that each Founder will
be exchanging and the aggregate number of such Option Shares, which aggregate
number may not exceed the applicable threshold as set forth in subsections
2.1(a)-2.1(d) above.

        3. DPI's Right to Exchange DPI Stock for SP Stock. Subject to the terms
and conditions specified in this Section 3 and the valuation mechanism set forth
in Section 4, the Founders, and each of them, hereby grant to DPI certain option
rights, exercisable only after the IPO, to exchange shares of the common stock
of DPI for IPO-Time Shares (such rights collectively referred to as the "DPI
CALL OPTIONS"). The IPO-Time Shares shall be acquired from the respective
Founders on a pro-rata basis (based on the number of IPO-Time Shares each such
Founder (together with such Founder's transferees of IPO-Time Shares) then holds
in relation to the IPO-Time Shares then held by all the Founders).

           3.1 DPI's Call Options if SP Valuation is Greater than $30 Million.
The following provisions shall apply if as of the applicable Anniversary Date
the value of the total number of shares of common stock of SP outstanding as of
the applicable Anniversary Date (assuming full conversion and exercise of all
convertible or exercisable securities) is determined pursuant to Section 4 to be
equal to or greater than $30 million.

               (a) First Call Option. By valid delivery of a Call Option Notice
(as set forth below), DPI may elect to exchange on the First Anniversary Date
shares of common stock of DPI for up to twenty-five percent (25%) of the
IPO-Time Shares (less any IPO-Time Shares previously sold to DPI under Section 2
or 3).

               (b) Second Call Option. By valid delivery of a Call Option Notice
(as set forth below), DPI may elect to exchange on the Second Anniversary Date
shares of common stock of DPI for up to fifty percent (50%) of the IPO-Time
Shares (less any IPO-Time Shares previously sold to DPI under Section 2 or 3).

               (c) Third Call Option. By valid delivery of a Call Option Notice
(as set forth below), DPI may elect to exchange on the Third Anniversary Date
shares of common stock of DPI for up to seventy-five percent (75%) of the
IPO-Time Shares (less any IPO-Time Shares previously sold to DPI under Section 2
or 3).

               (d) Fourth Call Option. By valid delivery of a Call Option Notice
(as set forth below), DPI may elect to exchange on the Fourth Anniversary Date
shares of common stock of DPI for up to one hundred percent (100%) of the
IPO-Time Shares (less any IPO-Time Shares previously sold to DPI under Section 2
or 3).

                                      -3-
<PAGE>   4

           3.2 DPI's Call Options if SP Valuation is Less than $30 Million. The
following provisions shall apply if as of the applicable Anniversary Date the
value of the total number of shares of common stock of SP outstanding as of the
applicable Anniversary Date (assuming full conversion and exercise of all
convertible or exercisable securities) is determined pursuant to Section 4 to be
less than $30 million.

               (a) Fifty Percent Call Option. By valid delivery of a Call Option
Notice (as set forth below), DPI may elect to exchange on the Third Anniversary
Date shares of common stock of DPI for up to fifty percent (50%) of the IPO-Time
Shares (less any IPO-Time Shares previously sold to DPI under Section 2 or 3).

               (b) One Hundred Percent Call Option. By valid delivery of a Call
Option Notice (as set forth below), DPI may elect to exchange on the Fourth
Anniversary Date shares of common stock of DPI for up to one hundred percent
(100%) of the IPO-Time Shares (less any IPO-Time Shares previously sold to DPI
under Section 2 or 3).

           3.3 Call Option Notice. Each time DPI elects to exercise a DPI Call
Option, DPI shall deliver not less than thirty (30) days prior to the applicable
Anniversary Date of the IPO a written notice (each a "CALL OPTION NOTICE") to
each of the Founders. Such Call Option Notice shall be signed by an officer of
DPI and shall state the numbers of Option Shares that DPI will be acquiring,
which aggregate number may not exceed the applicable threshold as set forth in
Sections 3.1 and 3.2 above.

           3.4 Overlap. If the Founders Put Option and DPI Call Option are
exercised simultaneously, the total IPO-Time Shares sold shall not exceed the
greater of the number of shares allowed under the applicable respective
subsections of Section 2 and 3. Example: for the First Anniversary Date, the
Founders Put Option is exercised for 10% of the IPO-Time Shares and the DPI Call
Option is exercised (under Section 3.1(a)) for 22% of the IPO-Time Shares. 25%
of the IPO-Time Shares shall be sold on the First Anniversary Date.

        4. Determination of Number of DPI Shares to be Exchanged. To determine
how many shares of DPI common stock shall be exchanged for the IPO-Time Shares
identified in a Put Option Notice and/or a Call Option Notice the following
provisions shall apply. The number of shares of DPI common stock to be delivered
to a particular Founder for his IPO-Time Shares shall be (X) the product of (i)
the per-share value of a share of common stock of SP divided by the 10 Day
Average (as defined below) of a share of common stock of DPI times (ii) the
number of IPO-Time Shares being sold by him to DPI pursuant to such Put Option
Notice and/or Call Option Notice, plus (Y) the quotient of (i) the product of
(1) the 10 Day Average of a share of DPI common stock less $8.00, times (2) the
applicable Personal Factor (as defined below), times (3) the number of IPO-Time
Shares being sold by him to DPI pursuant to such Put Option Notice and/or Call
Option Notice, divided by (ii) the 10 Day Average of a share of DPI common
stock. For Richard Fine, the "PERSONAL FACTOR" is 0.13549; for Boris Klebansky,
the "PERSONAL FACTOR" is 0.13549; and for Arnold Hagler, the "PERSONAL FACTOR"
is 0.57645. The per-share value of the shares of common stock of SP shall be
determined by dividing (A) the product of (i) SP's total revenues for the 12
calendar months completed immediately before the applicable Anniversary Date
times (ii) the DPI Price to Revenue Ratio (as defined below) by (B) the total
number of shares of common stock of SP outstanding as of the applicable
Anniversary Date (assuming full conversion and exercise of all convertible or
exercisable securities). The "DPI

                                      -4-
<PAGE>   5

PRICE TO REVENUE RATIO" shall be calculated by dividing (C) the product of (i)
the average closing prices of DPI's common stock over the 10 trading days ending
on the last trading day of the calendar month before the applicable Anniversary
Date as quoted on the Nasdaq National Market or other principal national
securities exchange (or a similar national quotation system) (the "10 DAY
AVERAGE") times (ii) the total number of shares of common stock of DPI
outstanding as of the last trading day of the calendar month before the
applicable Anniversary Date (assuming full conversion and exercise of all
convertible and exercisable securities) by (D) the total revenues for DPI for
the 12 calendar months ending on such last trading day of the calendar month
before the applicable Anniversary Date.

        5. SP Spin-off. If at any time the Founders collectively notify DPI that
they believe that the value of SP may be greater as an entity separate from DPI
than as a subsidiary of DPI, DPI agrees to negotiate and discuss with the
Founders in good faith with respect to how the greatest value for SP may be
achieved (either as a continuing subsidiary of DPI, spun off in a public
offering, or otherwise).

        6. Miscellaneous.

           6.1 Successors and Assigns. The terms and conditions of this
Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or
their respective successors and assigns any rights, remedies, obligations, or
liabilities under or by reason of this Agreement, except as expressly provided
in this Agreement.

           6.2 Governing Law. This Agreement shall be governed by and construed
under the laws of the State of California as applied to agreements among
California residents entered into and to be performed entirely within
California.

           6.3 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

           6.4 Titles and Subtitles. The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

           6.5 Notices. Unless otherwise provided, any notice required or
permitted under this Agreement shall be given in writing and shall be deemed
effectively given upon personal delivery to the party to be notified or one
business day after delivery by facsimile, electronic mail or overnight courier
or upon deposit with the United States Post Office, by registered or certified
mail, postage prepaid and addressed to the party to be notified at the address
indicated for such party on the signature page hereof, or at such other address
as such party may designate by ten (10) days' advance written notice to the
other parties.

           6.6 Expenses. Each party shall bear its own expenses for the
transactions contemplated by this Agreement. If any action at law or in equity
is necessary to enforce or interpret the terms of this Agreement, the prevailing
party shall be entitled to reasonable

                                      -5-
<PAGE>   6

attorneys' fees, costs and necessary disbursements in addition to any other
relief to which such party may be entitled.

           6.7 Amendments and Waivers. Any term of this Agreement may be amended
and the observance of any term of this Agreement may be waived (either generally
or in a particular instance and either retroactively or prospectively), only
with the written consent of SP, DPI and a majority in interest of the Founders.
Any amendment or waiver effected in accordance with this paragraph shall be
binding upon each party hereto.

           6.8 Severability. If one or more provisions of this Agreement are
held to be unenforceable under applicable law, such provision shall be excluded
from this Agreement and the balance of the Agreement shall be interpreted as if
such provision were so excluded and shall be enforceable in accordance with its
terms.

           6.9 Entire Agreement. This Agreement (together with the Stock
Purchase Agreement of even date) constitutes the full and entire understanding
and agreement between the parties with regard to the subjects hereof and
thereof.

           6.10 Legends. Each share certificate representing SP common stock
owned by any Founder (or any transferee of a Founder) shall be imprinted with a
legend specifying that the shares are subject to this Agreement.

           6.11 Restricted Securities. Any and all shares of DPI common stock
issued hereunder shall be unregistered under the Securities Act of 1933 and all
"blue sky" laws. They cannot be resold unless they are registered under such Act
or are exempt from registration. They may never be able to be resold. The
Founders agree that they will be acquiring any such DPI stock for their own
respective accounts for investment, and not with a view to any distribution
thereof.

           6.12 Lockup Agreement. In connection with any initial public offering
which DPI may ever choose to make of its common stock, if the underwriter(s) in
such IPO request the Founders to sign a customary lockup agreement and complete
a customary NASD questionnaire, each Founder agrees to sign such customary
lockup agreement with respect to any and all shares of DPI common stock which at
the time are owned by or subject to an option in favor of such Founder and to
complete such customary NASD questionnaire.

                                      -6-
<PAGE>   7

        IN WITNESS WHEREOF, the parties have executed this Rights Agreement as
of the date first above written.

STRUCTURAL PROTEOMICS, INC.           DISCOVERY PARTNERS
                                      INTERNATIONAL, INC.

By: /s/ Arnold Hagler                 By: /s/ Jack Fitzpatrick
    -----------------------------         --------------------------------------

Address:                              Address:  9640 Towne Centre Drive
         ------------------------               --------------------------------

                                                San Diego, CA 92121
         ------------------------               --------------------------------

Fax:                                  Fax:      (858) 455-8088
         ------------------------               --------------------------------

E-Mail:                               E-Mail:   jackf@discoverypartners.com
         ------------------------               --------------------------------

FOUNDERS

          /s/ Richard Fine                      /s/ Boris Klebansky
          -----------------------               --------------------------------
          Richard Fine                          Boris Klebansky

Address:  428 Bedford Rd              Address:  4 Adele Av.
          -----------------------               --------------------------------

          Ridgewood, NJ 07450                   Dematest, NJ 07627
          -----------------------               --------------------------------

Fax:      fine@ix.netcom.com          Fax:      201-784-2042
          -----------------------               --------------------------------

E-Mail:   201-444-2490                E-Mail:   bkc@intac.com
          -----------------------               --------------------------------

                                                /s/ Arnold Hagler
                                                --------------------------------
                                                Arnold Hagler

                                      Address:  P.O. Box 12067 La Jolla CA 92039
                                                --------------------------------

                                                --------------------------------

                                      Fax:
                                                --------------------------------

                                      E-Mail:   arnie@sciencemedia.com
                                                --------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00011-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00011-of-00352.parquet"}]]